X-ray-Structure-Based Identification of Compounds with Activity against Targets from Different Families and Generation of Templates for Multitarget Ligand Design
暂无分享,去创建一个
[1] Chung-Eun Ha,et al. Structural basis of albumin–thyroxine interactions and familial dysalbuminemic hyperthyroxinemia , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[2] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[3] Kenneth M Merz,et al. The Ecstasy and Agony of Assay Interference Compounds. , 2017, ACS chemical neuroscience.
[4] Zukang Feng,et al. Ligand Depot: a data warehouse for ligands bound to macromolecules , 2004, Bioinform..
[5] J. Bajorath,et al. Polypharmacology: challenges and opportunities in drug discovery. , 2014, Journal of medicinal chemistry.
[6] Jürgen Bajorath,et al. Analog series-based scaffolds: computational design and exploration of a new type of molecular scaffolds for medicinal chemistry , 2016, Future science OA.
[7] Cathy H. Wu,et al. UniProt: the Universal Protein knowledgebase , 2004, Nucleic Acids Res..
[8] J. Baell,et al. Chemistry: Chemical con artists foil drug discovery , 2014, Nature.
[9] Michael M. Hann,et al. RECAP — Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry. , 1998 .
[10] J. Baell,et al. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.
[11] M. Rosini,et al. Polypharmacology: the rise of multitarget drugs over combination therapies. , 2014, Future medicinal chemistry.
[12] J. Ruland,et al. Structural analysis of phenothiazine derivatives as allosteric inhibitors of the MALT1 paracaspase. , 2013, Angewandte Chemie.
[13] M. Lilly,et al. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase , 2007, Molecular Cancer Therapeutics.
[14] Daniel J. Warner,et al. Matched molecular pairs as a medicinal chemistry tool. , 2011, Journal of medicinal chemistry.
[15] Jürgen Bajorath,et al. Computational design of new molecular scaffolds for medicinal chemistry, part II: generalization of analog series-based scaffolds , 2017, Future science OA.
[16] M. Romão,et al. Structural insights into xenobiotic and inhibitor binding to human aldehyde oxidase. , 2015, Nature chemical biology.
[17] Alexander Tropsha,et al. Phantom PAINS: Problems with the Utility of Alerts for Pan-Assay INterference CompoundS , 2017, J. Chem. Inf. Model..
[18] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[19] Paul Webb,et al. Thyroxine-Thyroid Hormone Receptor Interactions* , 2004, Journal of Biological Chemistry.
[20] B. Shoichet. Screening in a spirit haunted world. , 2006, Drug discovery today.
[21] Jürgen Bajorath,et al. Highly Promiscuous Small Molecules from Biological Screening Assays Include Many Pan-Assay Interference Compounds but Also Candidates for Polypharmacology. , 2016, Journal of medicinal chemistry.
[22] J. Lehár,et al. Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.
[23] Jameed Hussain,et al. Computationally Efficient Algorithm to Identify Matched Molecular Pairs (MMPs) in Large Data Sets , 2010, J. Chem. Inf. Model..
[24] Jürgen Bajorath,et al. Matched molecular pairs derived by retrosynthetic fragmentation , 2014 .
[25] Jin-jian Lu,et al. Multi-Target Drugs: The Trend of Drug Research and Development , 2012, PloS one.
[26] M L Bolognesi,et al. Polypharmacology in a single drug: multitarget drugs. , 2013, Current medicinal chemistry.
[27] Jürgen Bajorath,et al. Computational Method for the Systematic Identification of Analog Series and Key Compounds Representing Series and Their Biological Activity Profiles. , 2016, Journal of medicinal chemistry.
[28] Thorsten Meinl,et al. KNIME: The Konstanz Information Miner , 2007, GfKl.
[29] Jürgen Bajorath,et al. How Frequently Are Pan-Assay Interference Compounds Active? Large-Scale Analysis of Screening Data Reveals Diverse Activity Profiles, Low Global Hit Frequency, and Many Consistently Inactive Compounds. , 2017, Journal of medicinal chemistry.
[30] S. Withers,et al. Order and disorder: differential structural impacts of myricetin and ethyl caffeate on human amylase, an antidiabetic target. , 2012, Journal of medicinal chemistry.
[31] W. Geldenhuys,et al. Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders , 2013, Expert opinion on drug discovery.
[32] A. Cavalli,et al. Multitarget Drug Discovery and Polypharmacology , 2016, ChemMedChem.
[33] B. Shoichet,et al. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.
[34] K. Shokat,et al. Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.
[35] J. Bajorath,et al. Compound promiscuity: what can we learn from current data? , 2013, Drug discovery today.
[36] David Weininger,et al. SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules , 1988, J. Chem. Inf. Comput. Sci..